SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-000980
Filing Date
2024-01-04
Accepted
2024-01-04 06:04:44
Documents
16
Period of Report
2024-01-03
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea191024-8k_jasper.htm   iXBRL 8-K 36264
2 CERTIFICATE OF SECOND AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE O ea191024ex3-1_jasper.htm EX-3.1 17010
7 GRAPHIC ex3-1_002.jpg GRAPHIC 4773
8 GRAPHIC ex3-1_001.jpg GRAPHIC 5404
  Complete submission text file 0001213900-24-000980.txt   295260

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20240103.xsd EX-101.SCH 3928
4 XBRL DEFINITION FILE jspr-20240103_def.xml EX-101.DEF 26833
5 XBRL LABEL FILE jspr-20240103_lab.xml EX-101.LAB 37093
6 XBRL PRESENTATION FILE jspr-20240103_pre.xml EX-101.PRE 25457
10 EXTRACTED XBRL INSTANCE DOCUMENT ea191024-8k_jasper_htm.xml XML 5723
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 24509697
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)